Get the Stockscreener App
13.44
3.07%
0.40
Freenome, Inc. Common stock stock is traded at $13.44, with a volume of 469.66K.
It is up +3.07% in the last 24 hours and down -16.99% over the past month.
See More
Previous Close:
$13.04
Open:
$13.05
24h Volume:
469.66K
Relative Volume:
0.76
Market Cap:
$1.44B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-4.07%
1M Performance:
-16.99%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$12.48
$13.71
52-Week Range:
$9.97
$17.50
Freenome, Inc. Common stock Stock (FRNM) Company Profile
Name
Freenome, Inc. Common stock
Sector
Industry
Phone
-
Address
-
Compare FRNM vs TMO, DHR, NTRA, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FRNM
Freenome, Inc. Common stock
|
13.44 | 1.44B | 0 | 0 | 0 | 0.00 |
TMO
Thermo Fisher Scientific Inc
|
704.15 | 260.36B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
234.07 | 164.55B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
424.27 | 61.16B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
181.48 | 51.16B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
476.88 | 46.85B | 3.77B | 449.25M | 240.68M | 7.8556 |
Freenome, Inc. Common stock Stock (FRNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-26 | Initiated | Guggenheim | Buy |
| Aug-18-26 | Initiated | TD Cowen | Buy |
| Aug-17-26 | Initiated | BTIG Research | Buy |
| Aug-17-26 | Initiated | Jefferies | Buy |
| Aug-14-26 | Initiated | Leerink Partners | Outperform |
Freenome, Inc. Common stock Stock (FRNM) Latest News
Form 4 Freenome Inc For: 20 October By Investing.com - Investing.com South Africa
Form 4 Freenome Inc For: 20 October By Investing.com - Investing.com Nigeria
Freenome, Inc.Common stock (Nasdaq:FRNM) Stock Quote - The Chronicle-Journal
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
IPO Calendar for: - Yahoo! Finance Canada
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
An updated blood test detected 18.2% of advanced precancerous growths, versus 13.7% in the earlier study. - Stock Titan
IPO Calendar for: - Yahoo! Finance Canada
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.ca
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - kalkine.com.au
Freenome (FRNM) CEO left with 345,976 shares after tax withholding - Stock Titan
Roche group holds 18.7M Freenome (NASDAQ: FRNM) shares - Stock Titan
Freenome Registers Up To 75.2 Million Shares For Sale - Yahoo Finance
Jefferies initiates Freenome stock with buy rating on cancer screening potential - Investing.com Nigeria
Freenome, Inc. (FRNM) insider converts 30,000 Class B shares - Stock Titan
Freenome, Inc. (PCSC) director reports common stock and option stakes - Stock Titan
Freenome, Inc. (FRNM) director Douglas Van Oort details equity stake - Stock Titan
Freenome, Inc. (FRNM) CEO details stock and option positions - Stock Titan
Freenome (Nasdaq:FRNM)Stock Analysis - Simply Wall Street
symbol__ Stock Quote Price and Forecast - CNN
Total common shares outstanding of Freenome, Inc. – NASDAQ:FRNM - TradingView
Freenome, Inc. Common stock (FRNM) Historical Quotes - Nasdaq
Form 4 Perceptive Capital Solutions Corp For: 22 July - Investing.com
Freenome, Inc.: FRNM Stock Price Quote & News - Robinhood
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch - Wilson Sonsini
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome, Inc. (FRNM) stock price, news, quote and history - Yahoo Finance UK
Freenome (FRNM) Stock Price, News & Analysis - Stock Titan
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - globenewswire.com
Cancer detection specialist Freenome lists on Nasdaq through special purpose merger - mugglehead.com
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection - BioSpace
Upcoming & Recent IPO'sIPOs Calendar - Yahoo! Finance Canada
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Cancer test developer Freenome's SPAC backers seek one-year extension to close deal - The Business Journals
Freenome to go public via PCSC SPAC (PCSC): $240M PIPE, $525M pro forma cash - Stock Titan
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform - PR Newswire
Cancer detection firm Freenome to go public via $330 million SPAC deal - STAT
PCSC SEC FilingsPerceptive Capital Solutions Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Perceptive Capital Solutions (PCSC) Stock Price, News & Analysis - Stock Titan
CNS Pharmaceuticals, Inc. Common Stock (CNSP) Historical Quotes - Nasdaq
AXGN Stock Price and Chart — NASDAQ:AXGN - TradingView
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance UK
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Upcoming & Recent IPO'sIPOs Calendar - Yahoo Finance
Freenome, Inc. Common stock Stock (FRNM) Financials Data
There is no financial data for Freenome, Inc. Common stock (FRNM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):